/stocks — the workspaceLOADING
All ACAD SEC filings, by type → · Earnings date & implied move · Search inside filings
ACADIA PHARMACEUTICALS INC (ACAD) is a pharmaceutical preparations company. Piotroski F-Score 4/7. 2 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-04 from ACAD's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind ACAD’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31. original 1968 formula; calibrated on manufacturers, read financials/REITs with care
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from ACAD’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on ACAD plus an auto-SWOT — built from ACAD's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate ACAD using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has ACAD been issuing shares? Offering history →
↓ Download the fiscal-year statement table (XLSX) · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
No lawmaker has disclosed a trade in ACAD under the STOCK Act.
No tracked institution reported a position in ACAD in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| IJR iShares Core S&P Small-Cap ETF | 0.17% | 2026-06-30 |
| IWM iShares Russell 2000 ETF | 0.10% | 2026-06-30 |
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
| ITOT iShares Core S&P Total US Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Projected from ACAD's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentACAD files or announces.
ACAD has rallied after 7 of its last 8 earnings reports.
Each figure is one earnings reaction — how much ACAD moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
ACAD has traded higher after most recent earnings releases.
The average is inflated by its most volatile prints (+16.4% and -0.9%).
A more typical earnings reaction has been approximately ±2.5%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-04 | +12.5% |
| 2026-05-06 | +0.9% |
| 2026-02-25 | +0.2% |
| 2025-11-05 | -0.9% |
| 2025-08-06 | +3.2% |
| 2025-05-07 | +16.4% |
| 2025-02-26 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| +1.7% |
| 2024-11-06 | +14.7% |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SELL | $587K | view → |
| Thompson Elizabeth H.Z.EVP, Head of Research & Dev | SELL | $433K | view → |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SELL | $298K | view → |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SELL | $114K | view → |
| Schneyer Mark C.EVP, CHIEF FINANCIAL OFFICER | SELL | $76K | view → |
| Kihara JamesPRINCIPAL ACCOUNTING OFFICER | SELL | $29K | view → |
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.
Every figure is from ACAD’s SEC cash-flow statement. This describes how management deployed cash last period — it is not a grade of that deployment, not a forecast, and not investment advice. Whether reinvesting, paying down debt, or returning cash was the right call depends on the return each earns, which the filings do not settle. Educational information only.
Head office: San Diego, California, United States · the company’s charter and its head office are in different states.
Source: the cover page of ACADIA PHARMACEUTICALS INC’s 10-Q filed 2026-08-05, on EDGAR. Filings checked 2026-10-16. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works